期刊
ZEITSCHRIFT FUR GASTROENTEROLOGIE
卷 49, 期 2, 页码 211-224出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/s-0029-1245705
关键词
small bowel intestinal bacterial overgrowth; diverticular disease; infectious colitis; lactose intolerance; pseudomembranous colitis; irritable bowel syndrome
Rifaximin, a non-resorbable broadband antibiotic, was approved in Germany 2 years ago for the treatment of traveller's diarrhoea caused by non-invasive enteropathogens. On account of the very good tolerance and the high efficacy against almost all enteropathogens this pharmaceutical, which has been available for 25 years, bears a high potential in many other indications which are currently under clinical investigations, including: symptomatic uncomplicated diverticular disease, Clostridium difficile-associated diarrhoea and pseudomembranous colitis, small bowel intestinal bacterial over-growth, irritable bowel syndrome and hepathic encephalopathy. The present overview demonstrates potential indications in the field of gastroenterology and critically reviews the significance of rifiximin in the treatment of these diseases based on the latest clinica data.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据